Study of the effect of olaparil on the treatment of platinum-sensitive advanced recurrent ovarian cancer
Liqiang Han 

First Hospital of Shanxi Medical University , Shanxi Province Taiyuan City , 030001;

Abstract：Objective: To analyze the effect of olaparil on the treatment of platinum-sensitive advanced recurrent ovarian cancer. Methods: 82 patients with platinum-sensitive recurrent ovarian cancer were selected and divided into control and study groups with 41 patients in each group. Patients in the trial group received adjuvant therapy with oral olapparil tablets within 8 weeks after the administration of 6 courses of chemotherapy on the TC regimen, while the control group did not receive special drugs after 8 weeks of chemotherapy with the TC regimen. After the treatment, the treatment effect and treatment quality of the two groups were compared. Results: After treatment, CA125 and HE4 decreased significantly in all patients, and the difference was significant (P <0.05); the incidence of oral mucositis in the test group was lower than that in the control group (P <0.05). The incidence of adverse reactions and QOL scores in the other two groups were not significant (P> 0.05). Conclusion: The treatment of platinum-sensitive recurrent ovarian cancer can significantly improve the objective remission and disease control effect, and reduce the level of serum tumor markers.

Keywords：platinum-sensitive, recurrent ovarian cancer, olaparil; CA125, HE4, treatment effect

References

[1] Barnard ME, Farland LV, Yan B, Wang J, Trabert B, Doherty JA, Meeks HD, Madsen M, Guinto E, Collin LJ, Maurer KA, Page JM, Kiser AC, Varner MW, Allen-Brady K, Pollack AZ, Peterson KR, Peterson CM, Schliep KC. Endometriosis Typology and Ovarian Cancer Risk. JAMA. 2024 Aug 13;332(6):482-489. doi: 10.1001/jama.2024.9210. .

[2] Jamali Z, Razipour M, Zargar M, Ghasemnejad-Berenji H, Akrami SM. Ovarian cancer extracellular vesicle biomarkers. Clin Chim Acta. 2025 Jan 15;565:120011. doi: 10.1016/j.cca.2024.120011. Epub 2024 Oct 20.

[3] Pullen RL Jr. Ovarian cancer. Nursing. 2024 Jun 1;54(6):17-28. doi: 10.1097/NSG.0000000000000002. Epub 2024 May 17.

[4] Richardson DL, Moore KN, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, Castro CM, Provencher D, Matulonis UA, Stec J, Wang Y, Method M, O'Malley DM. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2024 Jun;185:186-193. doi: 10.1016/j.ygyno.2024.01.045. Epub 2024 Mar 5.

[5] Ji S, Chen L, Yu Y, Chen X, Wei L, Gou L, Shi C, Zhuang S. A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis. J Ovarian Res. 2025 Jan 30;18(1):18. doi: 10.1186/s13048-025-01599-1. PMID: 39885555;

[6] Zhou Y, Xu J. Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis. World J Surg Oncol. 2024 Oct 21;22(1):276. doi: 10.1186/s12957-024-03562-8. PMID: 39434111;

[7] Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, Vergote I, Parma G, Nøttrup TJ, Lebreton C, Fasching PA, Pisano C, Manso L, Bourgeois H, Runnebaum I, Zamagni C, Hardy-Bessard AC, Schnelzer A, Fabbro M, Schmalfeldt B, Berton D, Belau A, Lotz JP, Gropp-Meier M, Gladieff L, Lück HJ, Abadie-Lacourtoisie S, Pujade-Lauraine E, Ray-Coquard I. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Int J Gynecol Cancer. 2024 Apr 1;34(4):550-558. doi: 10.1136/ijgc-2023-004995. PMID: 38129136;

[8] Schouten PC, Schmidt S, Becker K, Thiele H, Nürnberg P, Richters L, Ernst C, Treilleux I, Medioni J, Heitz F, Pisano C, Garcia Y, Petru E, Hietanen S, Colombo N, Vergote I, Nagao S, Linn SC, Pujade-Lauraine E, Ray-Coquard I, Harter P, Hahnen E, Schmutzler RK. Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations. JAMA Netw Open. 2024 Apr 1;7(4):e245552. doi: 10.1001/jamanetworkopen.2024.5552.

[9] Miao H, Meng H, Zhang Y, Chen T, Zhang L, Cheng W. FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism. Cell Death Differ. 2024 Apr;31(4):497-510. doi: 10.1038/s41418-024-01263-z. Epub 2024 Feb 19.

[10] Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugère C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. J Clin Oncol. 2024 Apr 10;42(11):1288-1300. doi: 10.1200/JCO.23.01214. Epub 2024 Feb 1.